



# RSV Surveillance Methods: Sentinel Site Aspects

WHO Mid-Term Review Meeting of the Global RSV Surveillance Pilot

Dr. Christina Bancej - Canada



# Overview: Sentinel Site Aspects


- First countries launched December 2016
- 12 countries actively submitting data
- 1-9 in-country sentinel sites
- Targets pediatric(12) and adult(9)
- Hospital/SARI(10), ambulatory/ILI(5), symptom-based(12)
- 8,702 ILI/SARI cases; 1,412 RSV+




# Scope of Pilot by Country

Country	No. Sites	Type of site	Target Population	Start Date (YYYY - MM)*	Last Date (YYYY - MM)*	Cumulative Cases
Argentina	5	Hospital	Ped & adult	2016-12	2017-10	528
Australia	1	Hospital	Pediatric	2017-07	2017-12	638
Brazil	1	N/R	Pediatric	2017-05	2017-10	86
Chile	2	Hospital	Ped & adult	2016-12	2017-09	511
Cote d'Ivoire	9	Comm & Hosp	Ped & adult	2016-12	2017-07	686
Egypt	N/R	Hospital	Ped & adult	2016-07	2017-10	354
India	7	Comm & Hosp	Ped & adult	2017-01	2017-12	860
Mongolia	7	Comm & Hosp	Ped & adult	2017-01	2017-11	352
Mozambique	4	Comm & Hosp	Ped & adult	2017-01	2017-11	440
Russian Federation	N/R	Hospital	Ped & adult	2016-12	2017-11	752
South Africa	2	N/R	Pediatric	2016-12	2017-10	1671
Thailand	9	Comm & Hosp	Ped & adult	2017-01	2017-11	1849


# RSV Detections by Onset Date: All Pilot Countries 2016/17 (N=1,368)



## Number of Patients and Number and % RSV Positive: All Pilot Countries 2016/17



# Mean, Minimum and Maximum Patient Age: All Sentinel Sites, 2016/17



## Case Definitions

- **SARI\***: requiring hospitalization; onset <10 days; fever  $\geq 38$  C; and cough/SoB.
  - Infants <6 mo: apnoea and/or sepsis
- **ARI**: acute (sudden onset) and respiratory infection ( $\geq 1$  of SoB/cough; sore throat; coryza).
- **ILI\***: acute (onset <10 days); measured fever of  $\geq 38$  C, and cough.

*\*Extended SARI, ILI: fever not present*

# Case Definitions Used

Country	ILI	ILI w/o fever	ARI	SARI	SARI w/o fever	Symptom-based	% Hospitalized
Argentina	No	No	Infrequent	Yes	Yes	Yes	99.4
Australia	No	No	No	Yes	Yes	Yes	100
Brazil	N/R	N/R	N/R	N/R	N/R	Yes	N/R
Chile	N/R	N/R	N/R	N/R	N/R	Yes	100
Cote d'Ivoire	Yes	Infrequent	Infrequent	Yes	Infrequent	Yes	42.0
Egypt	N/R	N/R	N/R	Yes	N/R	Yes	N/R
India	Yes	Infrequent	Infrequent	Yes	Yes	Yes	89.7
Mongolia	Yes	Yes	No	Yes	Yes	Yes	84.1
Mozambique	Yes	Yes	No	No	Yes	Yes	70.2
Russian Federation	N/R	N/R	N/R	Yes	Infrequent	Yes	100
South Africa	N/R	N/R	N/R	N/R	N/R	Yes	N/R
Thailand	Yes	Yes	No	Yes	Yes	Yes	54.2



# Symptom Correlates of RSV Positivity (All Ages)

Symptom	RSV+ (vs RSV -) N=1,412	Flu+ (vs Flu-) N=1,407
Acute Illness	↑ 98%	↓92
Fever -History	↓ 52%	≈64
Fever- Measured	↑ 82%	↓69
Cough	↑ 98%	≈93
Cold	↑ 73%	↓43
Chest	↑ 58%	↓28
Shortness of Breath	↑ 64%	↓38
Wheeze	↑ 40%	↓18
Sore Throat	↓20%	↑48
Apnea	↑4.4%	↓1.2
Sepsis	≈4.1%	↓1.5

## Sentinel Site Aspects: Challenges

- Sentinel selection – target population, severity
- Training
- Patient selection
- Case-based reporting
- Clinical severity, prophylaxis, treatment, outcome indicators
- Specimen handling
- Laboratory reporting
- Case-based and lab linkage
- Reporting data to the GISRS platform

# Sentinel Site Aspects: Questions & Comments

**Thank you!**